Abstract：
BACKGROUND: The survival of patients with neuroendocrine tumors has substantially improved with modern treatment options. Although the associated carcinoid syndrome can be diagnosed early and controlled effectively, cardiologists still encounter patients with cardiac manifestations, particularly among individuals with persistently high levels of vasoactive mediators. Treatment options have been limited to surgical valve replacement in fully manifested disease. Since surgery is not always feasible, transcatheter valve implantation is becoming an interesting alternative.
METHODS: A case of a 50-year-old woman with carcinoid syndrome and right-sided valvular heart disease is presented. Moderate pulmonary valve stenosis and severe tricuspid valve regurgitation were diagnosed during the evaluation and treatment of neuroendocrine tumor. The possibility of rare valve involvement and the need for interdisciplinary cooperation in the diagnosis, monitoring and treatment of patients with neuroendocrine tumors producing vasoactive substances must be emphasized.
CONCLUSIONS: The patient had a typically presenting carcinoid syndrome with a rare cardiac manifestation. Although monitoring and treatment were carried out in accordance with recommendations and appropriate to the clinical condition, rapid progression of the metastatic disease ultimately precluded invasive cardiac intervention.
METHODS: A case of a 50-year-old woman with carcinoid syndrome and right-sided valvular heart disease is presented. Moderate pulmonary valve stenosis and severe tricuspid valve regurgitation were diagnosed during the evaluation and treatment of neuroendocrine tumor. The possibility of rare valve involvement and the need for interdisciplinary cooperation in the diagnosis, monitoring and treatment of patients with neuroendocrine tumors producing vasoactive substances must be emphasized.
CONCLUSIONS: The patient had a typically presenting carcinoid syndrome with a rare cardiac manifestation. Although monitoring and treatment were carried out in accordance with recommendations and appropriate to the clinical condition, rapid progression of the metastatic disease ultimately precluded invasive cardiac intervention.
摘要：
背景：采用现代治疗方案，神经内分泌肿瘤患者的生存率有了显著提高。虽然相关类癌综合征可以早期诊断和有效控制，心脏病学家仍然会遇到有心脏表现的患者，特别是在血管活性介质持续高水平的个体中。治疗选择仅限于完全表现疾病的外科瓣膜置换。因为手术并不总是可行的，经导管瓣膜植入正在成为一个有趣的选择。
方法：介绍一例50岁女性，患有类癌综合征和右侧心脏瓣膜病。在评估和治疗神经内分泌肿瘤时，诊断为中度肺动脉瓣狭窄和重度三尖瓣关闭不全。罕见瓣膜介入的可能性以及诊断中跨学科合作的必要性，必须强调对产生血管活性物质的神经内分泌肿瘤患者的监测和治疗。
结论：该患者患有典型的类癌综合征，并伴有罕见的心脏表现。尽管监测和治疗是根据建议进行的，并且适合于临床情况，转移性疾病的快速进展最终排除了侵入性心脏介入治疗。
方法：介绍一例50岁女性，患有类癌综合征和右侧心脏瓣膜病。在评估和治疗神经内分泌肿瘤时，诊断为中度肺动脉瓣狭窄和重度三尖瓣关闭不全。罕见瓣膜介入的可能性以及诊断中跨学科合作的必要性，必须强调对产生血管活性物质的神经内分泌肿瘤患者的监测和治疗。
结论：该患者患有典型的类癌综合征，并伴有罕见的心脏表现。尽管监测和治疗是根据建议进行的，并且适合于临床情况，转移性疾病的快速进展最终排除了侵入性心脏介入治疗。
